397 related articles for article (PubMed ID: 25404569)
1. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study.
Singh D; Jones PW; Bateman ED; Korn S; Serra C; Molins E; Caracta C; Gil EG; Leselbaum A
BMC Pulm Med; 2014 Nov; 14():178. PubMed ID: 25404569
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
[TBL] [Abstract][Full Text] [Related]
3. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).
Bateman ED; Chapman KR; Singh D; D'Urzo AD; Molins E; Leselbaum A; Gil EG
Respir Res; 2015 Aug; 16(1):92. PubMed ID: 26233481
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis.
Miravitlles M; Chapman KR; Chuecos F; Ribera A; Gil EG
Int J Chron Obstruct Pulmon Dis; 2016; 11():2041-53. PubMed ID: 27621610
[TBL] [Abstract][Full Text] [Related]
5. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.
Donohue JF; Soong W; Wu X; Shrestha P; Lei A
Respir Med; 2016 Jul; 116():41-8. PubMed ID: 27296819
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.
D'Urzo AD; Singh D; Donohue JF; Kerwin EM; Ribera A; Molins E; Chuecos F; Jarreta D; Gil EG
Int J Chron Obstruct Pulmon Dis; 2019; 14():479-491. PubMed ID: 30880938
[TBL] [Abstract][Full Text] [Related]
8. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
[TBL] [Abstract][Full Text] [Related]
9. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients.
Singh D; Magnussen H; Kirsten A; Mindt S; Caracta C; Seoane B; Jarreta D; Garcia Gil E
Pulm Pharmacol Ther; 2012 Jun; 25(3):248-53. PubMed ID: 22497752
[TBL] [Abstract][Full Text] [Related]
10. A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease.
D'Urzo A; Rennard S; Kerwin E; Donohue JF; Lei A; Molins E; Leselbaum A
Respir Med; 2017 Apr; 125():39-48. PubMed ID: 28340861
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study.
Vogelmeier C; Paggiaro PL; Dorca J; Sliwinski P; Mallet M; Kirsten AM; Beier J; Seoane B; Segarra RM; Leselbaum A
Eur Respir J; 2016 Oct; 48(4):1030-1039. PubMed ID: 27492833
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison.
Medic G; Lindner L; van der Weijden M; Karabis A
Adv Ther; 2016 Mar; 33(3):379-99. PubMed ID: 26883661
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of aclidinium/formoterol versus monotherapies and aclidinium versus placebo in Chinese and other Asian patients with moderate-to-severe COPD: The AVANT Phase 3 study.
Sun Y; Molins E; Daoud SZ; Trivedi R; Stewart C; Lamarca R; Bharali P; Garcia-Gil E
Respir Med; 2023 Nov; 218():107393. PubMed ID: 37640273
[TBL] [Abstract][Full Text] [Related]
14. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.
Sethi S; Kerwin E; Watz H; Ferguson GT; Mroz RM; Segarra R; Molins E; Jarreta D; Garcia Gil E
Int J Chron Obstruct Pulmon Dis; 2019; 14():667-682. PubMed ID: 30962681
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.
Jones PW; Rennard SI; Agusti A; Chanez P; Magnussen H; Fabbri L; Donohue JF; Bateman ED; Gross NJ; Lamarca R; Caracta C; Gil EG
Respir Res; 2011 Apr; 12(1):55. PubMed ID: 21518460
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E
Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study.
Beier J; Kirsten AM; Mróz R; Segarra R; Chuecos F; Caracta C; Gil EG
COPD; 2013 Aug; 10(4):511-22. PubMed ID: 23819698
[TBL] [Abstract][Full Text] [Related]
18. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients.
Rennard SI; Scanlon PD; Ferguson GT; Rekeda L; Maurer BT; Garcia Gil E; Caracta CF
Clin Drug Investig; 2013 Dec; 33(12):893-904. PubMed ID: 24085591
[TBL] [Abstract][Full Text] [Related]
19. Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study.
Beier J; Mroz R; Kirsten AM; Chuecos F; Gil EG
Int J Chron Obstruct Pulmon Dis; 2017; 12():1731-1740. PubMed ID: 28652725
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
Kerwin EM; D'Urzo AD; Gelb AF; Lakkis H; Garcia Gil E; Caracta CF;
COPD; 2012 Apr; 9(2):90-101. PubMed ID: 22320148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
